Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase I Trial of bacTRL-IL-12 in Adult Subjects With Advanced, Treatment-refractory Solid Tumours

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04025307
Recruitment Status : Recruiting
First Posted : July 18, 2019
Last Update Posted : March 31, 2020
Sponsor:
Information provided by (Responsible Party):
Iqvia Pty Ltd

Brief Summary:

This study is as an open-label study to be conducted at multiple study centres across New Zealand and Australia designed to characterise the safety, tolerability and preliminary assessment of the anti-tumour efficacy of bacTRL-IL-12 after intravenous (IV) infusion.

The study will consist of a screening period (Day -14 to Day -2), treatment and observation (Day 1 to Day 22), safety follow-up period (Day 28 to Day 31), and efficacy follow-up period (until progression, death, revocation of consent, or lost to follow-up).


Condition or disease Intervention/treatment Phase
Cancer - Solid Tumours Drug: bacTRL-IL-12 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 38 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multi-centre, Open-label, Phase I Trial of bacTRL-IL-12 in Adult Subjects With Advanced, Treatment-refractory Solid Tumours
Actual Study Start Date : August 5, 2019
Estimated Primary Completion Date : March 11, 2021
Estimated Study Completion Date : March 11, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: bacTRL-IL-12
single-dose, 1 mL IV infusion of bacTRL-IL-12
Drug: bacTRL-IL-12
bacTRL-IL-12 is a live, genetically modified Bifidobacterium longum (B longum), for administration via IV infusion. The probiotic bacteria selectively colonize solid tumour tissues and are engineered to deliver genetic material encoding the pro-inflammatory transgene Interleukin-12 (IL-12). Plasmid DNA encoding the IL-12 transgene is delivered to the patient's cells within the tumor microenvironment, whereupon IL-12 is expressed to stimulate local and systemic anti-tumour immune responses.




Primary Outcome Measures :
  1. Incidence and severity of adverse events according to NCI CTCAE [ Time Frame: day 31 safety follow up ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Adults (18 years or older);
  2. Capable of providing informed consent;
  3. Advanced and/or metastatic, histologically-documented, measurable (per iRECIST) solid tumours for which there are no other standard therapy options available that are acceptable to the subject;
  4. Eastern Cooperative Oncology Group status of 0 or 1;
  5. Adequate haematological status (regardless of transfusions) defined as:

    • Absolute neutrophil count ≥ 1.5 x 109/L;
    • Platelets ≥ 100 x 109/L;
    • Haemoglobin ≥ 9g/dL;
  6. Adequate renal function, defined as estimated serum creatinine clearance > 45mL/minute calculated using Cockcroft-Gault equation
  7. Adequate coagulation function, defined as:

    • International Normalised Ration <1.5 x upper limit of normal (ULN) for that laboratory
    • Partial thromboplastin time <1.5 x ULN
    • Exception: monitoring parameters must be within therapeutic range for subjects receiving anti-coagulation therapy
  8. Adequate hepatic function, defined as:

    • Total bilirubin < 1.5 x ULN unless considered due to Gilbert's disease;
    • Alanine aminotransferase and aspartate aminotransferase < 1.5 x ULN or < 3 x ULN with documented liver metastases;
  9. Recovery from the toxicities of previous anti-cancer drugs or radiotherapy to Grade 0 or 1 (or to baseline if condition was pre-existing);
  10. A female subject is eligible to participate if she in not pregnant, not breastfeeding, and at least 1 of the following conditions applies:

    • Not of childbearing potential, defined as surgically sterile (documented hysterectomy, bilateral salpingectomy or bilateral oophorectomy) or postmenopausal *no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy; however, in the absence of 12 months of amenorrhea, a single FSH measurement is sufficient);
    • Of childbearing potential and agrees to use a highly effective method of contraception consistently during the treatment period and for at least 60 days after that dose of study treatment;
  11. A male subject with a female partner of childbearing potential is eligible to participate if he agrees to use acceptable contraception during the treatment period and for at least 60 days after the last dose of study treatment and refrains from donating sperm during this period;
  12. Agree to increase oral sugar intake during the treatment period.

Exclusion Criteria:

  1. Presence or history of brain metastases or abscess;
  2. Presence of known or suspected ongoing ischemia of non-tumor tissues that may be inadvertently colonized by bacteria including:

    • Ischemic peripheral vascular disease, myocardial infarction within the past 6 months;
    • Congestive heart failure > class II New York Heart Association;
    • Unstable angina (anginal symptoms at rest) or new onset angina (commenced within the last 3 months);
    • Patent foramen ovale;
    • Prior history or current bacterial endocarditis,
    • Existing thrombus (either arterial or venous) as well as known history of deep vein thrombosis, permanent pacemakers, automated implantable cardioverter-defibrillators, left ventricular assist devices, or other intravascular cardiac device, known arteriovenous malformations;
    • Cerebrovascular event, including transient ischemic attacks within the past 6 months;
  3. An artificial implant that cannot be easily removed (e.g., heart valves, prosthetic hips or knees, or other devices) that could allow inadvertent bacterial colonization;
  4. Abnormal fluid collections (e.g. ascites and/or pericardial and/or pleural effusions) that could allow inadvertent bacterial colonization;
  5. Has tumor masses immediately adjacent to, and/or with infiltration into, large arteries, veins or vessels;
  6. Bacteremia and/or abscess and/or treatment with systemic (oral or IV) antibiotics within 4 weeks prior to dosing;
  7. Anticipated exposure to systemic antibiotics within 4 weeks of dosing;
  8. Positive for human immunodeficiency virus, hepatitis B or hepatitis C at screening;
  9. Treatment with radiation therapy to a visceral organ or tumors within 2 weeks prior to dosing;
  10. Treatment with any programmed cell death protein-1 and/or programmed cell death ligand 1 inhibiting agent within 2 weeks prior to dosing;
  11. Treatment with any investigational agent for treatment of cancer or related comorbidity within 4 weeks prior to dosing;
  12. Treatment with any chemotherapy or major surgery within 6 weeks prior to dosing;
  13. History of allergic reactions attributed to compounds of similar chemical or biologic composition to agent(s) or other agents used in study;
  14. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, autoimmune disorder, or psychiatric illness/social situations that would limit compliance with study requirements;
  15. Any other reason that, in the opinion of the investigator and/or sponsor, precludes the subject from participating in the trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04025307


Contacts
Layout table for location contacts
Contact: Rebecca Ho +61 434 563 486 rebecca.ho@iqvia.com
Contact: Michelle Jones mjones@symvivo.com

Locations
Layout table for location information
Australia
Monash Medical Centre Recruiting
Melbourne, Australia
Contact: Karen Gillett         
Sponsors and Collaborators
Iqvia Pty Ltd
Layout table for additonal information
Responsible Party: Iqvia Pty Ltd
ClinicalTrials.gov Identifier: NCT04025307    
Other Study ID Numbers: bacTRL-IL-12-001
First Posted: July 18, 2019    Key Record Dates
Last Update Posted: March 31, 2020
Last Verified: March 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms